0001209191-22-009565.txt : 20220214
0001209191-22-009565.hdr.sgml : 20220214
20220214195800
ACCESSION NUMBER: 0001209191-22-009565
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220210
FILED AS OF DATE: 20220214
DATE AS OF CHANGE: 20220214
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BJERKHOLT ERIC
CENTRAL INDEX KEY: 0001197350
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37345
FILM NUMBER: 22636490
MAIL ADDRESS:
STREET 1: 132 PURDURE AVENUE
CITY: KENGSINGTON
STATE: CA
ZIP: 94708
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CHINOOK THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001435049
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 FAIRVIEW AVENUE NORTH, SUITE 900
CITY: SEATTLE
STATE: WA
ZIP: 98109
BUSINESS PHONE: 206-485-7051
MAIL ADDRESS:
STREET 1: 400 FAIRVIEW AVENUE NORTH, SUITE 900
CITY: SEATTLE
STATE: WA
ZIP: 98109
FORMER COMPANY:
FORMER CONFORMED NAME: ADURO BIOTECH, INC.
DATE OF NAME CHANGE: 20111107
FORMER COMPANY:
FORMER CONFORMED NAME: ADURO BIOTECH
DATE OF NAME CHANGE: 20080514
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-02-10
0
0001435049
CHINOOK THERAPEUTICS, INC.
KDNY
0001197350
BJERKHOLT ERIC
C/O CHINOOK THERAPEUTICS, INC.
400 FAIRVIEW AVE. NO., 9TH FLOOR
SEATTLE
WA
98102
0
1
0
0
Chief Financial Officer
Common Stock
2022-02-10
4
M
0
2434
A
23098
D
Common Stock
2022-02-11
4
S
0
895
12.7412
D
22203
D
Restricted Stock Units (RSU)
2022-02-10
4
M
0
2434
0.00
D
2024-02-10
Common Stock
2434
4870
D
Restricted stock units convert into common stock on a one-for-one basis.
Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.64 to $12.74, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on February 10, 2022, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date.
/s/ Kirk Schumacher, Attorney-in-Fact
2022-02-14